Big Pharma has slowed down their buy outs of late because
Big Pharma has slowed down their buy outs of late because of using early promising phase 2 data that never came to fruition and many different pharmaceutical companies lost billions on buying on speculation. They want to see results that will be a guarantee or already have a BLA approved before buying. I think their motto became fool me once shame on you... fool me twice shame on me...
Big Pharma can’t stand any more buy out shame. They want the real deal already approved with BLA’s before they convince their board to buy a biotech. That is until recent covid purchases. But what drug has been a knock out? What drug will be the one to save many lives? Are they buying the right biotech? So many to choose from. Is it a last man standing for Severe to Critical? I think not...
It’s a great thing that we as Cytodyn have so many irons in the fire. Makes us really expensive after our first BLA achieves approval with so many more on the cusp of the pipeline just waiting for Mr. Rahman to file. Let’s think about this... filing for 8 approvals by either EUA or BLA and throw in a possible BTD. By the time Vyrologix is realized as a gem... it will be a possible mega equal to most big Pharma.
Then maybe a possible merger. The potential numbers by years end of $75-$100 makes us very expensive to buy. If we throw in the BTD for cancer in a 96 billion dollar market... We don’t need any stinking merger. We will be larger than half of the big Pharma’s by then. Maybe we buy out a few of them?
8
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...
Continue Reading
Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....
Continue Reading
Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...
Continue Reading
MV Throws Support Behind Aesch for FTA Role In this wild world where public transit feels the heat from financial burdens, MV Transportation's recent move to support Mark Aesch for the Federal Transit Administration's top spot isn’t just a nod of approval—it's a full-blown trumpet blast. They're not just doling out a basic endorsement here; they're practically waving...
Continue Reading
What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...
Continue Reading
Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...
Continue Reading
Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...
Continue Reading
WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...
Continue Reading
The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...
Continue Reading
BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...
Continue Reading
Top 5 Most Recently Viewed Articles
WTW Expands Through Innovative Acquisitions Willis Towers Watson Public Ltd., known as WTW, is making headlines with its ambitious strategy to enhance its technology-enabled insurance and workplace benefits services. By announcing two consequential acquisitions, WTW aims to broaden its reach in the middle market while modernizing its client interactions significantly....
Continue Reading
Microsoft's Recent Downgrade by Analysts Analysts at D.A. Davidson have made headlines by downgrading Microsoft's (NASDAQ: MSFT) rating from Buy to Neutral. They have kept a price target of $475, reflecting ongoing evaluations of Microsoft's market strategies and performance. Factors Contributing to the Downgrade A key reason for this downgrade is the increasing...
Continue Reading
Portman Ridge Finance Corporation Stock Overview In the current economic landscape, Portman Ridge Finance Corporation (NASDAQ: PTMN) has seen its stock touch a 52-week low, now priced at $16.19. This significant drop highlights a shift in investor sentiment, with key indicators such as the Relative Strength Index (RSI) signaling that the stock may be oversold. Notably,...
Continue Reading
Miami International Holdings Reports Trading Results Miami International Holdings, Inc., a technology-driven leader in financial markets, has announced significant trading results for July 2025. The company operates several exchanges, including MIAX, MIAX Pearl, MIAX Emerald, MIAX Sapphire, and MIAX Futures. These results demonstrate a capacity for growth and stability in...
Continue Reading
Unveiling Innovations at CES 2025 At a highly anticipated event in Las Vegas, Intel took the stage at CES 2025 to reveal its latest technological advancements in mobile computing and edge solutions. With the launch of the new Intel Core Ultra (Series 2) processors, Intel is set to lead the charge in revolutionizing the way businesses, creators, and gaming enthusiasts...
Continue Reading